353 related articles for article (PubMed ID: 11173606)
1. Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).
Honn KV; Aref A; Chen YQ; Cher ML; Crissman JD; Forman JD; Gao X; Grignon D; Hussain M; Porter AT; Pontes EJ; Powell I; Redman B; Sakr W; Severson R; Tang DG; Wood DP
Pathol Oncol Res; 1996; 2(3):191-211. PubMed ID: 11173606
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
4. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
5. The spectrum of morphology in non-neoplastic prostate including cancer mimics.
Montironi R; Scarpelli M; Mazzucchelli R; Cheng L; Lopez-Beltran A
Histopathology; 2012 Jan; 60(1):41-58. PubMed ID: 22212077
[TBL] [Abstract][Full Text] [Related]
6. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
7. Prognostic markers in clinically localized prostate cancer.
Pettaway CA
Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
[TBL] [Abstract][Full Text] [Related]
8. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in prostate cancer.
Stattin P
Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
[TBL] [Abstract][Full Text] [Related]
10. Differential diagnosis of glandular proliferations in the prostate. A conventional and immunohistochemical approach.
Helpap B
Virchows Arch; 1998 Nov; 433(5):397-405. PubMed ID: 9849853
[TBL] [Abstract][Full Text] [Related]
11. Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP).
Garde SV; Sheth AR; Venkatesan VM; Panchal CJ; Porter AT; Grignon DJ
Cancer Lett; 1994 Apr; 78(1-3):11-7. PubMed ID: 7514089
[TBL] [Abstract][Full Text] [Related]
12. Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Horchani A; Oueslati R
Tunis Med; 2013 Jul; 91(7):458-63. PubMed ID: 24008878
[TBL] [Abstract][Full Text] [Related]
13. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
14. High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen.
Cao KY; Mao XP; Wang DH; Xu L; Yuan GQ; Dai SQ; Zheng BJ; Qiu SP
Prostate; 2007 Dec; 67(16):1791-800. PubMed ID: 17929272
[TBL] [Abstract][Full Text] [Related]
15. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
16. [Differential diagnosis of prostate cancer: impact of pattern analysis and immunohistochemistry].
Bonkhoff H
Pathologe; 2005 Nov; 26(6):405-21. PubMed ID: 16205899
[TBL] [Abstract][Full Text] [Related]
17. [Benign mimickers of the prostate cancer. Diagnostic challenges].
Compérat E; Varinot J; Srigley JR
Ann Pathol; 2013 Aug; 33(4):237-46. PubMed ID: 23954116
[TBL] [Abstract][Full Text] [Related]
18. A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines.
Garde SV; Sheth AR; Porter AT; Pienta KJ
Cancer Lett; 1993 Jul; 70(3):159-66. PubMed ID: 7689036
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
20. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
